Business
Stoke Therapeutics Announces CEO Transition
Edward M. Kaye, M.D., to Step Down as Chief Executive Officer Director Ian F. Smith Appointed Interim Chief Executive Officer Arthur Tzianabos Appointed
About this update from Stoke Therapeutics, Inc.
[{"type":"text","content":"\nEdward M. Kaye, M.D., to Step Down as Chief Executive Officer\n\nDirector Ian F. Smith Appointed Interim Chief Executive Officer\n\nArthur Tzianabos Appointed Interim Executive Chairman of the Board\n\nBoard of Directors Initiates Search for Permanent Chief Executive Officer\n\n BEDFORD, Mass.--(BUSINESS WIRE)--\nStoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome.\n\nToday the Company announced that Edward M. Kaye, M.D., has decided to step down from his role as Chief Executive Officer effective as of March 19, 2025. To facilitate a smooth transition, Dr. Kaye will serve as an advisor to the Company and will continue to serve as a Director on Stoke’s Board. Effective March 19, 2025, Ian F. Smith has been appointed Interim Chief Executive Officer. The current Chairman of the Board Arthur Tzianabos, Ph.D., has been appointed Interim Executive Chairman. He will support Mr. Smith and Dr. Kaye through the transition and lead the search for a permanent Chief Executive Officer.\n\nDr. Tzianabos said, “On behalf of the Board, I would like to thank Ed for his invaluable contributions to Stoke over the last seven years. Ed’s vision and experience were instrumental in translating Stoke’s science into a first-in-class potential disease-modifying medicine for Dravet syndrome. Ed successfully led the Company from a startup through many key development milestones, creating a strong foundation for continued success and future growth as we enter late-stage clinical development and prepare for commercialization. We look forward to continuing to benefit from Ed’s expertise as a board member and advisor.”\n\nDr. Tzianabos continued, “We are pleased to have Ian step in as Interim CEO to lead Stoke while the Board conducts its search for a permanent CEO. Ian’s experience leading teams, developing and commercializing medicines for rare pediatric diseases, and time spent working with the Stoke team as an advisor and director over the past two years will provide continuity and will support continued advancement of our strategic and growth initiatives.”\n\nDr. Kaye said, “It has been a privilege le...